Open access
Open access
Powered by Google Translator Translator

All Posts

M-A: Corticosteroids in COVID-19 and non-COVID-19 ARDS

20 Apr, 2021 | 06:11h | UTC

Corticosteroids in COVID-19 and non-COVID-19 ARDS: a systematic review and meta-analysis – Intensive Care Medicine

 


M-A: Diagnostic performance of different sampling approaches for SARS-CoV-2 RT-PCR testing

20 Apr, 2021 | 06:09h | UTC

Diagnostic performance of different sampling approaches for SARS-CoV-2 RT-PCR testing: a systematic review and meta-analysis – The Lancet Infectious Diseases

Commentary: Beyond COVID-19—will self-sampling and testing become the norm? – The Lancet Infectious Diseases

Related Meta-analysis: Saliva and nasopharyngeal swab nucleic acid amplification have similar diagnostic accuracy for the detection of SARS-CoV-2 AND Saliva vs. nasopharyngeal swabs equally sensitive for Covid-19 diagnosis

 


[News release – not published yet] Sputnik V demonstrates 97.6% efficacy according to the analysis of data of 3.8 million vaccinated persons in Russia

20 Apr, 2021 | 06:08h | UTC

Sputnik V demonstrates 97.6% efficacy according to the analysis of data of 3.8 million vaccinated persons in Russia

 

Commentary on Twitter

 


COVID-19 dynamics after a national immunization program in Israel

20 Apr, 2021 | 06:06h | UTC

COVID-19 dynamics after a national immunization program in Israel – Nature Medicine

 

Commentary on Twitter

 


Large cohort finds low risk of SARS-CoV-2 cardiac involvement in young competitive athletes

20 Apr, 2021 | 06:04h | UTC

SARS-CoV-2 Cardiac Involvement in Young Competitive Athletes – Circulation

News Release: Study: Heart setbacks from COVID-19 unlikely in athletes – UW Medicine

 


UK researchers will deliberately reinfect people with COVID-19 in new ‘challenge study’

20 Apr, 2021 | 06:03h | UTC

UK researchers will deliberately reinfect people with COVID-19 in new ‘challenge study’ – LiveScience

See also: Young people to be reinfected with Covid for study – BBC

 


Pfizer CEO says third Covid vaccine dose likely needed within 12 months

20 Apr, 2021 | 06:02h | UTC

Pfizer CEO says third Covid vaccine dose likely needed within 12 months – CNBC

Commentary: Fully Vaccinated? Get Ready For Your Third Dose – Forbes

 


M-A: Prevalence of depression, anxiety and post-traumatic stress disorder in health care workers during the COVID-19 pandemic

20 Apr, 2021 | 06:00h | UTC

Prevalence of depression, anxiety and post-traumatic stress disorder in health care workers during the COVID-19 pandemic: A systematic review and meta-analysis – PLOS One

 


Clinical trial completion rates decline during COVID-19 pandemic

20 Apr, 2021 | 05:59h | UTC

Clinical trial completion rates decline during COVID-19 pandemic – Penn State

Original study: Assessing the Impact of COVID‐19 on Registered Interventional Clinical Trials – Clinical and Translational Science

 


Ten scientific reasons in support of airborne transmission of SARS-CoV-2

18 Apr, 2021 | 21:51h | UTC

Ten scientific reasons in support of airborne transmission of SARS-CoV-2 – The Lancet

Commentary: Recognising that coronavirus is predominantly spread through air would save lives, argues new assessment – University of Oxford

Animated Videos: Aerosols and making spaces safe – University of Oxford

 

Commentary on Twitter (thread – click for more)

 


Chlamydia and gonorrhea: new recommendation to screen sexually active patients under 30

20 Apr, 2021 | 05:42h | UTC

Guideline: Recommendation on screening for chlamydia and gonorrhea in primary care for individuals not known to be at high risk – Canadian Medical Association Journal

News release: Under 30 and sexually active? It’s a good idea to get tested for chlamydia and gonorrhea – Canadian Task Force on Preventive Health Care

Summary: Chlamydia and gonorrhea: new recommendation to screen sexually active patients under 30 – Canadian Task Force on Preventive Health Care

Related USPSTF Draft Statement: Screening for Chlamydia and Gonorrhea – U.S. Preventive Services Task Force

 


M-A: Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention

20 Apr, 2021 | 05:40h | UTC

Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis – The Lancet

 

Commentary on Twitter

 


RCT: Effect of infusion set replacement intervals on catheter-related bloodstream infections – “Infusion set use can be safely extended to 7 days with resultant cost and workload reductions”

20 Apr, 2021 | 05:37h | UTC

Effect of infusion set replacement intervals on catheter-related bloodstream infections (RSVP): a randomised, controlled, equivalence (central venous access device)–non-inferiority (peripheral arterial catheter) trial – The Lancet (link to abstract – $ for full-text)

 

Commentaries on Twitter

 


Perspective | The Confident Generalist: Putting The Primary Care Physician Back At The Center

20 Apr, 2021 | 05:35h | UTC

The Confident Generalist: Putting The Primary Care Physician Back At The Center – Health Affairs

 


Update on Corneal Transplant in 2021

20 Apr, 2021 | 05:33h | UTC

Update on Corneal Transplant in 2021 – JAMA (free for a limited period)

 


RCT: Atenolol has similar efficacy as propranolol with fewer adverse events in the treatment of problematic infantile hemangiomas

20 Apr, 2021 | 05:32h | UTC

Efficacy and Safety of Propranolol vs Atenolol in Infants With Problematic Infantile Hemangiomas: A Randomized Clinical Trial – JAMA Otolaryngology-Head & Neck Surgery (link to abstract – $ for full-text)

 


M-A: Intravenous tranexamic acid in surgical patients is not associated with increased risk of thromboembolic events and mortality

20 Apr, 2021 | 05:28h | UTC

Association of Intravenous Tranexamic Acid With Thromboembolic Events and Mortality: A Systematic Review, Meta-analysis, and Meta-regression – JAMA Surgery (free for a limited period)

Invited commentary: Tranexamic Acid and Safety in the Right Patient – JAMA Surgery (free for a limited period)

 

Commentary on Twitter

 


Outcome of acute kidney injury: how to make a difference?

20 Apr, 2021 | 05:26h | UTC

Outcome of acute kidney injury: how to make a difference? – Annals of Intensive Care

 


Study: Teprotumumab for patients with active thyroid eye disease

20 Apr, 2021 | 05:25h | UTC

Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials – The Lancet Diabetes & Endocrinology (link to abstract – $ for full-text)

 


Guidelines for Management of Patients with Anaplastic Thyroid Cancer

20 Apr, 2021 | 05:24h | UTC

2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer – Thyroid

Commentary: ATA Issues Guidelines for Managing Anaplastic Thyroid Cancer – HealthDay

 


Podcast: Management of Obesity Hypoventilation Syndrome

20 Apr, 2021 | 05:23h | UTC

#269 Obesity Hypoventilation Syndrome (OHS) and the Didgeridoo with Dr Aneesa Das – The Curbsiders

 


Podcast: Dementia Made Simple

20 Apr, 2021 | 05:21h | UTC

#268 Dementia Made Simple with Dr. Josh Uy – The Curbsiders

 


2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult

18 Apr, 2021 | 21:24h | UTC

2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult – Canadian Journal of Cardiology

 

Commentary on Twitter

 


ESC Consensus Document: Personalized exercise prescription in the prevention and treatment of arterial hypertension

18 Apr, 2021 | 21:22h | UTC

Personalized exercise prescription in the prevention and treatment of arterial hypertension: a Consensus Document from the European Association of Preventive Cardiology (EAPC) and the ESC Council on Hypertension – European Journal of Preventive Cardiology

News release: How to prevent and treat high blood pressure with exercise – European Society of Cardiology

 


RCT: No benefit from second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis

18 Apr, 2021 | 21:21h | UTC

Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial – The Lancet Neurology (link to abstract – $ for full-text)

 


Stay Updated in Your Specialty

No spam, just news.